

The ILBOW

Infinite Leverage Buy Out Without Debt

Presented by John Gorman

Founder, TCI & TCRA

The Opportunity

TCRA is a startup with patented Dark Lab Automation (DLA) technology poised to transform the global clinical laboratory market.

TCRA proposes a groundbreaking financial structure — the ILBOW — to unlock this value and fund a world-changing philanthropic mission.

\$1T

Royalty Potential

\$300B+

Company Valuation

\$0

Acquisition Cost

What is the ILBOW?

Infinite Leverage Buy Out Without Debt

A group of specially selected investors acquire TCRA while it is valueless — at zero cost — then use their combined commercial power to make those shares extraordinarily valuable.



Zero acquisition cost

B7 receive shares while TCRA has no value



Infinite leverage

No debt required — value created through commercial action



Philanthropic outcome

\$500B+ cash flow directed to world-changing causes

The Big 7

Seven world-class companies uniquely positioned to unlock TCRA's value

COMMERCIAL PARTNERS (B4)



Siemens

7% TCRA shares



Roche

7% TCRA shares



Danaher

7% TCRA shares



Abbott

7% TCRA shares

Install patented DLA in global clinical labs and collect \$1 trillion in royalties

UNDERWRITERS (U3)



Morgan Stanley

7% TCRA shares



Blackstone

7% TCRA shares



**Andreessen
Horowitz**

7% TCRA shares

How the ILBOW Works

01

Recruit influencers

TCI recruits Rh Club members and high-access individuals to approach B7, offering 3% TCRA shares

02

Grant shares at zero cost

B7 companies are granted 7% each of TCRA shares while the company is valueless — no cost to them

03

B4 announce intent to deploy DLA globally

The Big 4 clinical lab automation manufacturers announce their intent plan to develop and install patented DLA technology across the world's clinical laboratories

04

Value is created just by announcements alone

Investors see future royalty flow of \$1T. Underwriters price TCRA at \$300B+, each TCRA share becomes worth >\$300,000

Gain of Value Creation

\$1T

DLA royalties
over 20 years

\$300B+

NAV of future
cash flows

\$1M+

Cash flow per
TCRA share

>\$300K

Liquid NPV per
share instantly

Why This Works

The B7's combined high-finance and commercial strength means they can credibly mark up TCRA's net asset value north of \$300 billion. Their stature makes the success of TCRA almost certain — and their rewards will be more than sufficient to make their participation imperative.

TCRA Cap Sheet

ENTITY	ALLOCATION	ROLE
Siemens	7%	B4 — Commercial Partner
Roche	7%	B4 — Commercial Partner
Danaher	7%	B4 — Commercial Partner
Abbott	7%	B4 — Commercial Partner
Morgan Stanley	3%	U3 — Underwriter
Blackstone	3%	U3 — Underwriter
Andreessen Horowitz	3%	U3 — Underwriter
Rh Club / Recruiters	3%	Access & Influence
Foundations and TCI	60%	Philanthropy 50% - Founders 10%

The Philanthropic Mission



WIRhE

Funded with a \$10 billion instant cash endowment to eradicate Hemolytic Disease of the Fetus and Newborn (HDFN) from the entire world, forever.



\$500 Billion

Generated in total cash flow directed toward philanthropic causes — the largest philanthropic funding mechanism in history.

Next Steps



Engage B7 leadership

Through Rh Club members and high-access individuals with direct access to each company



Secure commitments

B7 companies promise to act in exchange for their 7% share allotment at zero cost



B4 Announce global DLA deployment

B4 partners install patented technology across the world's clinical laboratories



ILBOW valuation event

U3 underwriters find investors at \$300B+ valuation, generating returns for all stakeholders

The ILBOW

Transforming a zero-value startup into a \$300 billion company
that funds the eradication of a disease — forever.

John Gorman

Founder, TCI & TCRA